23/06/2026 Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Sanofi’s tolebrutinib approved in the EU for secondary progressive multiple sclerosis without relapses Abbive announced EC approval of risankizumab for the treatment of pediatric patients with oderate to severe plaque psoriasis Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia (Ref) Sanofi announced that the Ministry of Health, Labour and Welfare in Japan had granted marketing and

11/06/2026 Nipocalimab demonstrated a durable hemoglobin response and rapid onset of effect in a Phase 2/3 study in wAIHA Climb Bio announced initial Phase 1b data for budoprutug in ITP at EHA Congress 2026 Takeda’s Zasocitinib significantly outperformed deucravacitinib in a head-to-head Phase 3 Psoriasis Study Nipocalimab demonstrated a durable hemoglobin response and rapid onset of effect in a Phase 2/3 study in wAIHA (Ref) Johnson & Johnson presented results from the Phase

28/05/2026 Zenas BioPharma announced submission of BLA to US FDA for Obexelimab in IgG4-RD Innocare announced the acceptance of the NDA for Orelabrutinib in Primary ITP in China Zenas BioPharma announced submission of BLA to US FDA for Obexelimab in IgG4-RD (Ref) Zenas BioPharma announced the submission of its Biologics License Application (BLA) to the US FDA for obexelimab (CD19 and FcγRIIb) in Immunoglobulin G4-Related Disease (IgG4-RD). The BLA submission was supported by